Regulatory bodies like the FDA and EMA have specific programs to facilitate early access. For instance, the FDA's Expanded Access Program and the EMA's Compassionate Use Program provide frameworks for patients to receive investigational drugs. These programs ensure that patients have access while maintaining rigorous safety standards.
